The Science Based Targets initiative (SBTi) has validated Controlant’s near-term climate target to reduce scope 1 and 2 greenhouse gas (GHG) emissions by 42% by 2030. With a validated target, Controlant becomes one of the first companies among its global industry peers to have a validated science-based target. Joining the initiative is a vital step for Controlant in its mission to deliver zero-waste pharma supply chains and ensure its climate actions are in line with the latest climate science.
Controlant commits to reducing absolute scope 1 and scope 2 greenhouse gas emissions by 42% by 2030 from a 2022 base-year. The company is also committed to measuring and reducing its scope 3 emissions and has already measured the most significant scope 3 categories, such as purchased goods and services, waste generated in operations, business travel, and employee commute. Within those categories, Controlant has identified key opportunities to reduce emissions going forward. The company’s near-term target reflects the level of decarbonization required to keep global temperature increase to 1.5°C. This target was approved using a streamlined target validation route available to small and medium-sized enterprises.
Validation of Controlant’s science-based target marks an essential milestone on the company’s sustainability journey, demonstrating commitment to the environment and to stakeholders including customers, employees, investors, and the wider community.
"Controlant‘s solutions are designed to empower pharmaceutical companies to reduce waste in their supply chain. We have a significant opportunity to have a real impact on one of the world‘s most critical supply chains, guiding it toward a sustainable path. We are proud to join the Science Based Targets initiative, a global movement for ambitious corporate decarbonization. A science-based target is an important step in our sustainability journey and confirms our commitment to the sustainable delivery of medicine and vaccines to people around the world,“ says Ásthildur Otharsdóttir, Chairman of the Board of Controlant.“
A zero-waste pharma supply chain is only possible through innovative solutions that enable a circular economy to eliminate waste and pollution—every step of the way. A science-based target provides a clearly defined, credible, transparent, and effective pathway for the company to reduce its greenhouse gas emissions.
“Through our innovative solutions, we enable pharmaceutical companies and logistics services to deliver medicine safely, reliably, and transparently to people around the world, while eliminating waste along every step of the supply chain. A science-based target is an important tool in uniting our talented team around a shared vision for the future, and to channel our energy and focus our efforts on work that truly brings us closer to realizing zero-waste pharma supply chains,” says Gísli Herjólfsson, CEO and co-founder.
Controlant’s vision is to deliver zero-waste supply chains for its partners, customers, and the planet through digitalization, automation, and transformation of the pharma supply chain. We enable our customers to deliver on their climate strategies by providing them with the necessary analytics and real-time visibility to minimize waste and pollution in the pharma supply chain, resulting in less product loss and the production of safety stock.
With SBTi’s validation, the company is delivering on the climate commitments it communicated in January 2023, ahead of its year-end 2024 target. Starting in 2023, Controlant will report annually on its sustainability performance, including performance against its science-based target.
The Science Based Targets initiative (SBTi) is a global body enabling businesses to set ambitious emissions reduction targets in line with the latest climate science. It is focused on accelerating companies across the world to halve emissions before 2030 and achieve net-zero emissions before 2050. The initiative is a collaboration between the Carbon Disclosure Project (CDP), United Nations Global Compact, World Resources Institute (WRI), and World Wide Fund for Nature (WWF), and is one of the We Mean Business Coalition commitments. More information can be found on https://sciencebasedtargets.org/
Saga Card will bring unprecedented visibility into the journey of medicines and vaccines, from production to patient.
Controlant affirms its commitment to environmental transparency by disclosing its environmental impact through the Climate Disclosure Project (CDP), a global non-profit that runs the world’s leading environmental disclosure platform. In the first year of rating, CDP rates Controlant B- for its coordinated action on climate issues.
Controlant has been rated Silver in its 2024 EcoVadis sustainability assessment, placing the company among the top 15% of over 125,000 rated companies across industries. The Silver rating is a significant achievement in the second assessment year for Controlant, bumping the company up from a Bronze rating in the previous year. The rating is in line with Controlant ambitions to become a sustainability leader.